Condition (MeSH)
Peritonitis, Tuberculous
ClinicalTrials.gov lists 3 trials for Peritonitis, Tuberculous or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
3 of the 3 trials are tagged with Peritonitis, Tuberculous itself; the rest are tagged with a narrower condition beneath it.
When did Peritonitis, Tuberculous trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 3
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2020 | 1 |
| 2019 | 1 |
| 2008 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Peritonitis, Tuberculous trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 1 |
How many Peritonitis, Tuberculous trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 2 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Peritonitis, Tuberculous? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.